Pre-made Izuralimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-ICOS;PDCD1/PD-1 therapeutic antibody, Anti-AILIM/CD278/CVID1;CD279/SLEB2/hPD-1/hPD-l/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-287

Pre-made Izuralimab benchmark antibody (Bispecific Mixed mAb and scFv, anti-ICOS;PDCD1/PD-1 therapeutic antibody, Anti-AILIM/CD278/CVID1;CD279/SLEB2/hPD-1/hPD-l/hSLE1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-287-1mg 1mg Inquiry
GMP-Bios-ab-287-10mg 10mg Inquiry
GMP-Bios-ab-287-100mg 100mg Inquiry
GMP-Bios-ab-287-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Izuralimab biosimilar, Bispecific Mixed mAb and scFv, Anti-ICOS;PDCD1/PD-1 antibody: Anti-AILIM/CD278/CVID1;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody
INN Name Izuralimab
TargetICOS;PDCD1/PD-1
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1;na
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesXencor
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna